




Cancer Research

AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH



September 1, 1996
Volume 56 • Number 17
PP. 3855-4085
ISSN 0008-5472 • CNREA 8

AACR SPECIAL CONFERENCE IN CANCER RESEARCH

Disrupted Transcription Factors in Cancer



January 17-21, 1997

Hotel Del Coronado

San Diego, CA

CONFERENCE CHAIRPERSONS

Peter K. Vogt / La Jolla, CA

Frank J. Rauscher, III / Philadelphia, PA

SCIENTIFIC PROGRAM

Keynote Address

Carlo M. Croce / Philadelphia, PA

Basic Transcriptional Mechanisms

Robert Tjian / Berkeley, CA

Danny F. Reinberg / Piscataway, NJ

Arnold J. Berk / Los Angeles, CA

Development, Negative Regulators

Peter Gruss / Gottingen, Germany

David M. Livingston / Boston, MA

Eric N. Olson / Dallas, TX

Stuart Orkin / Boston, MA

Jean Y. J. Wang / La Jolla, CA

Grace Gill / Boston, MA

Solid Tumors I

Gilles Thomas / Paris, France

Christopher T. Denny / Los Angeles, CA

David Ron / New York, NY

Cory Abate-Shen / Piscataway, NJ

Leukemias I

Terry H. Rabbitts / Cambridge, England

Michael L. Cleary / Stanford, CA

Thomas A. Look / Memphis, TN

Richard J. Baer / Dallas, TX

Gary Gilliland / Boston, MA

Mark P. Kamps / La Jolla, CA

Solid Tumors II

Riccardo Dalla Favera / New York, NY

Frederic G. Barr / Philadelphia, PA

Garrett M. Brodeur / Philadelphia, PA

Saraswati Sukumar / Baltimore, MD

Leukemias II

Janet D. Rowley / Chicago, IL

Ronald M. Evans / La Jolla, CA

Paul P. Liu / Ann Arbor, MI

Yoshiaki Ito / Kyoto, Japan

Laurie H. Glimcher / Boston, MA

Clinical Applications

Samuel Waxman / New York, NY

Pier Pellicci / Milan, Italy

Phil Koeffler / Los Angeles, CA

*Applicants are encouraged to submit
abstracts for poster presentation.*

Application deadline: November 1, 1996

Information and Application Forms

American Association for Cancer Research
Public Ledger Building, Suite 816
150 South Independence Mall West
Philadelphia, PA 19106-3483

Phone: (215) 440-9300 • Fax: (215) 440-9313

E-mail: aacr@aol.com

AACR web site at <http://www.aacr.org>

CARCINOGENESIS FROM ENVIRONMENTAL POLLUTION: ASSESSMENT OF HUMAN RISK AND STRATEGIES FOR PREVENTION

Joint Meeting Organized by the
American Association for Cancer Research (AACR)
and the International Agency for Research on Cancer (IARC)

With the Collaboration of the Hungarian Cancer Society



October 6-9, 1996
Hotel Gellért
Budapest, Hungary



CONFERENCE CHAIRPERSONS
Frederica Perera / New York, USA
Paul Kleihues / Lyon, France

PROGRAM COMMITTEE

Hans-Olov Adami / Uppsala, Sweden
J. Carl Barrett / Research Triangle Park, USA
Paolo Boffetta / Lyon, France
Edward Bresnick / Worcester, USA
Mieczyslaw R. Chorąży / Gliwice, Poland
Joseph F. Fraumeni, Jr. / Bethesda, USA

Waun Ki Hong / Houston, USA
Margaret L. Kripke / Houston, USA
Kenneth Olden / Research Triangle Park, USA
Alán Pintér / Budapest, Hungary
Manfred F. Rajewsky / Essen, Germany
David Zaridze / Moscow, Russia

SCIENTIFIC PROGRAM

Keynote Address

Curtis C. Harris / Bethesda, USA

Cancer Incidence and Etiology

Witold A. Zatoński / Warsaw, Poland
Frederica Perera / New York, USA
J. Carl Barrett / Research Triangle Park, USA
Helmut Bartsch / Heidelberg, Germany

Air, Water, Food, and Soil Contamination

Radim J. Šrám / Prague, Czech Republic
Joellen Lewtas / Research Triangle Park, USA
Wieslaw Jedrychowski / Cracow, Poland
Olav Axelson / Linköping, Sweden

Ambient, Environmental, and Occupation Exposure and Cancer Risk

Mieczyslaw R. Chorąży / Gliwice, Poland
Alán Pintér / Budapest, Hungary
Kimmo Peltonen / Helsinki, Finland
Monica C. Hollstein / Heidelberg, Germany
Kari Hemminki / Stockholm, Sweden

Tobacco

Ivan Plesko / Bratislava, Slovakia
Barbara S. Hulka / Chapel Hill, USA
Paolo L. Vineis / Turin, Italy
Stephen S. Hecht / Valhalla, USA
Krystyna Frenkel / New York, USA
Bernadette Schoket / Budapest, Hungary

Strategies for Prevention

Waun Ki Hong / Houston, USA
I. Bernard Weinstein / New York, USA
Anna Tompa / Budapest, Hungary

Roundtable Discussion

Paul Kleihues / Lyon, France
Hans-Olov Adami / Uppsala, Sweden
Paolo Boffetta / Lyon, France
Edward Bresnick / Worcester, USA
Andrew E. Czeizel / Budapest, Hungary
Terri Damstra / Research Triangle Park, USA
Edith Olah / Budapest, Hungary
Kenneth Olden / Research Triangle Park, USA
Manfred F. Rajewsky / Essen, Germany
William A. Suk / Research Triangle Park, USA
David Zaridze / Moscow, Russia

Applicants are encouraged to submit abstracts for poster presentation.

Information and Application Forms

American Association for Cancer Research
Public Ledger Building, Suite 816
150 S. Independence Mall West
Philadelphia, PA 19106-3483
(215) 440-9300 (215) 440-9313 (FAX)
Email: aacr@aol.com



KEYSTONE SYMPOSIA

MOLECULAR AND CELLULAR BIOLOGY OF GENE THERAPY

Snowbird, Utah • April 13 - 19, 1997

Organizers: Helen M. Blau and James M. Wilson

BIOLOGY OF SARCOMAS - II: MOLECULAR, PATHOLOGIC AND ONCOLOGIC

ASPECTS OF MESENCHYMAL GROWTH AND DIFFERENTIATION

Copper Mountain, Colorado • February 22 - 27, 1997

Organizers: Richard B. Womer, Lee J. Helman and Frederic G. Barr

APOPTOSIS AND PROGRAMMED CELL DEATH

Tamarron, Colorado • February 18 - 23, 1997

Organizers: J. John Cohen and John Cidlowski

CELLULAR IMMUNOLOGY AND THE IMMUNOTHERAPY OF CANCER - III

Copper Mountain, Colorado • February 1 - 7, 1997

Organizers: Michael T. Lotze and Olivera J. Finn

GROWTH CONTROL

Keystone, Colorado • January 4 - 10, 1997

Organizers: Charles J. Sherr and Tony Hunter

Sponsored by Genentech, Inc.

Drawer 1630 • Silverthorne, CO 80498

1-800-253-0685 • 970-262-1230 • FAX: 970-262-1525

E-mail: keystone@symposia.com • Web site: <http://www.colorado.net/symposia>

THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER

Postdoctoral Fellowships in Molecular Cancer Biology

Postdoctoral positions open September 1, 1996 with a newly established research group at the M.D. Anderson Cancer Center for talented Ph.D. and/or M.D. scientists in the following disciplines:

APOPTOSIS. Current studies include: (1) mechanisms by which apoptotic responses to chemotherapy are modulated by growth factor-mediated signal transduction pathways and by regulators of cell cycle traversal; (2) mechanisms of apoptosis induced by therapeutic agents including the role(s) of anti- and pro-apoptotic gene products.

GROWTH FACTORS. Ongoing investigations include: (1) novel mechanisms of action of anti-EGF receptor monoclonal antibodies; (2) mechanisms of heregulin/NDF action; (3) regulatory interactions between receptor tyrosine kinases and estrogen receptors in breast carcinoma cells.

Cell Cycle. Research focuses on: (1) regulation of cyclin dependent kinase inhibitors (2) regulation of nuclear matrix proteins.

Experience in molecular biology, biochemistry, and signal transduction is desirable. For immediate consideration, please send curriculum vitae and names of three references to one of the three Principal Investigators in the group: Drs. John Mendelsohn, Rakesh Kumar, Zhen Fan, Laboratory of Cell Growth Regulation, University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd, Box 91, Houston, Texas 77030. An equal opportunity employer.

COVER LEGEND



Featured on this issue's cover is Arthur B. Pardee, a distinguished molecular biologist, who has been the recipient of many honors for his pioneering investigations on regulatory mechanisms, initially with bacteria and then with mammalian cells (summarized in *Adv. Cancer Res.*, 65: 213–228, 1994; *Protein Science*, 3: 1136–1139, 1994).

In his studies with *Escherichia coli*, Dr. Pardee discovered numerous major mechanisms for regulating enzyme activity, synthesis, and cell proliferation. One such mechanism is feedback inhibition of biochemical sequences, in which a product made after a half-dozen steps of the pathway of pyrimidine synthesis inhibits the first enzyme in the sequence. When overproduced, this product shuts down the whole pathway at its start, thereby providing a very tight control that avoids waste. Remarkably, the inhibitor and substrate do not look at all alike. A solution to this problem of apparent nonspecificity is that the enzyme comprises interacting proteins. The substrate binds to the catalytic partner and the inhibitor to the regulatory one, an initial example of allostery.

Another mechanism, discovered while Dr. Pardee was on sabbatical with Jacques Monod and Francois Jacob, is repression, in which a negatively regulating repressor protein binds to an enzyme's DNA and shuts down its transcription. This binding is released when a substrate-like molecule combines with the repressor and transcription starts.

Dr. Pardee also found links between macromolecular syntheses, such as stringent control, in which nucleic acid synthesis (as well as protein synthesis) depends upon available amino acids. Conversely, protein synthesis requires continual nucleic acid synthesis, a concept that was a forerunner of the discovery of mRNA. He discovered ribosomes in bacteria and isolated and crystallized the first active transmembrane transport protein.

In the 1960s, Dr. Pardee began to investigate deranged regulation in cancer, particularly the question of what goes wrong in cancers so that mammalian cells grow when and where they should not. A central idea is that proliferation depends upon switches between resting and growing states. His suggestion in 1964 that interactions of extracellular factors with membrane are important in the growth of cancer was far ahead of its time because growth factor receptors had not yet been discovered. Much evidence now supports his early hypothesis (done while on sabbatical with Sir Michael Stoker) that

the restriction (R) point mechanism located in late G₁ phase of the cell cycle, which limits onset of DNA synthesis, is the major subsequent intracellular control of cell proliferation. The cell cycle is not tightly controlled after a cell has passed the R point of no return. Dr. Pardee showed that this R point process requires a protein in sufficient quantity for DNA synthesis to be initiated. This protein has a short half-life in normal cells and is stabilized in tumor cells. A cancer cell thereby more easily proceeds beyond R than does a normal cell.

Dr. Pardee and colleagues studied control of the R protein by using transcription of mouse thymidine kinase (TK) as a marker for transition from G₁ to S. TK, like DNA-related events, is under the same general control by growth factors and inhibitors as is DNA synthesis itself. Because TK mRNA appears at the restriction point, one can apply molecular genetics. A minimal promoter DNA sequence determines turning on G₁-S-phase specific transcription of TK. A promoter-binding protein complex appears strikingly at this time, which includes retinoblastoma-related p107 protein, E2F, cyclin E, and cdk2 kinase. In transformed tumor-forming cells, a very different picture emerges, *i.e.*, TK controls and complexes are deranged.

Cyclins, particularly D and E, are major contributors to growth control. Alterations of cyclins in tumor cells allow G₁-S transcriptions more readily. Cyclins can appear at inappropriate times in cancer cells, so that one cyclin replacing another could signal faulty initiation of cell proliferation. Dr. Pardee concluded that cyclin E is most probably the R point protein. It is a single protein in normal cells, but it is grossly altered in size, amount, and activity in cancer cells. Changed cyclin E protein was seen in all the cancer tissues examined *in vivo versus* normal adjacent biopsy material. It may provide diagnostic and prognostic cancer markers.

Recently, Dr. Pardee has invented a general method, differential display, to detect the mRNAs expressed in a given cell type. Comparisons of displays of mRNA markers from different cells permit isolation of genes that are expressed differently in normal *versus* tumor cells. Hundreds of researchers are now using this method, and they have isolated numerous genes of interest.

Dr. Pardee received his B.S. in Chemistry from the University of California, Berkeley, in 1942, and his Ph.D. in Chemistry from the California Institute of Technology in 1947. While at Cal Tech, he worked with Nobel Laureate Linus Pauling. His postdoctoral studies with Van R. Potter, on one of the first Merck Fellowships, were in the area of cancer enzymology.

Dr. Pardee has authored nearly 400 original articles, reviews, and chapters, and he has received many honors throughout his distinguished career, including his election to membership in the prestigious National Academy of Sciences. His other achievements include his receipt of the Paul Lewis Award of the American Chemical Society (1960), the Sir H. A. Krebs Medal (1973), and the Rosensteil Medal (1975).

He has been a member of the American Association for Cancer Research (AACR) since 1979. He served on its Board of Directors from 1983–86 (*ex officio* from 1986–88) and on the Policy Committee from 1984–88, acting as its Chairperson in 1986–87. In addition, he has been active on the Awards Committee, chairing it in 1986–87, and he served on the Rhoads Award Committee in 1983–84 and the Clowes Award Committee in 1988–89. Most significantly, Dr. Pardee served as AACR President from 1985–86. Under his leadership, the first efforts to strengthen the Association's programs in molecular biology and genetics were launched. Now, the AACR membership includes thousands of molecular cancer researchers, and advances in molecular biology permeate all of the Association's scientific programs.

Sidney Weinhouse